News & Stories

Amylyx Pharmaceuticals Announces Topline Results From Global Phase 3 PHOENIX Trial of AMX0035 in ALS

We are sad to share that the results from Amylyx Pharmaceutical’s top line data of their phase 3 clinical trial indicates that treatment with Relyvrio showed no better results than treatment with a placebo. The company will be sharing plans about the treatment in the next 8 weeks and may withdraw the drug from the market.

To the many people with ALS who have tried Relyvrio: the ALS United Connecticut community shares our deepest regrets. We had all hoped for a positive result from the trial. There are two other FDA approved therapies for ALS available to all people living with ALS – Riluzole and Radicava. Speak with your ALS clinic team for information and guidance.

In the meantime, this inspires us to forge ahead and continue funding ALS research to bring new treatments through the clinical trial and FDA approval process. There are many therapies in study and we remain hopeful for the future.

Share This Page: